Evidence map›Paper›PMID 39840688›Full record

SynthesisEuropean journal of clinical investigation2025

Imaging predictors of adverse prognosis in Fabry disease cardiomyopathy: A systematic review and meta-analysis.

Kamil Stankowski, Stefano Figliozzi, Thanakorn Rojanathagoon, Dimitrios Bampatsias, Dimitrios Klettas, Lorenzo Monti, Renato Bragato, Pier-Giorgio Masci, Marco Francone, Gianluigi Condorelli and 4 more

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in European journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Staging of Fabry cardiomyopathy in clinical practice: an algorithm proposal.International journal of cardiology. Heart & vasculature · 2026
    Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kamil StankowskiIRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Stefano FigliozziIRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.ORCID https://orcid.org/0000-0003-2991-1548
Thanakorn RojanathagoonSchool of Medicine, University of Nottingham, Nottingham, UK.
Dimitrios BampatsiasDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
Dimitrios KlettasDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
Lorenzo MontiIRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Renato BragatoIRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Pier-Giorgio MasciSchool of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
Marco FranconeIRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Gianluigi CondorelliIRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Massimo ImbriacoDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Maurizio PieroniCardiovascular Department, San Donato Hospital, Arezzo, Italy.
Antonia CamporealeMultimodality Cardiac Imaging Section, IRCCS Policlinico San Donato, San Donato Milanese, Italy.
Georgios GeorgiopoulosDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.ORCID https://orcid.org/0000-0001-7661-5253

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCardiac involvement represents the main cause of death in patients with Fabry disease (FD). Echocardiography and cardiovascular magnetic resonance (CMR) have an established diagnostic role, but their prognostic value remains unresolved. This systematic review and meta-analysis sought to assess the prognostic implications of imaging parameters in FD.

methodsPubMed, ClinicalTrials.gov, Embase, Cochrane Library and Web of Science databases were searched for studies from inception through 1 May 2024. Studies including FD patients undergoing baseline imaging assessment and clinical follow-up were selected. Pre-defined study outcomes were a cardiovascular endpoint and a composite clinical endpoint. The study protocol was registered in PROSPERO (ID CRD42022342394).

resultsFourteen studies, including 1713 FD patients (44.7% males), were selected. At pooled analysis, late gadolinium enhancement (hazard ratio [HR]: 4.45; 95% CI: 2.82-7.02), left atrium volume indexed (HR: 1.02 per mL/m

conclusionsSeveral imaging parameters were significant predictors of adverse clinical outcomes in patients with FD. Late gadolinium enhancement showed the strongest association with adverse prognosis.

Indexed as

CardiomyopathiesFabry DiseaseEchocardiographyGadoliniumHumansMagnetic Resonance ImagingMagnetic Resonance Imaging, CinePrognosisStroke VolumeGadoliniumcardiovascular magnetic resonanceFabry diseaseglobal longitudinal strainlate gadolinium enhancementleft ventricular hypertrophytransthoracic echocardiography

Identifiers

PMID39840688
PMCPMC12011678

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.